A recent phase III clinical trial evaluating the efficacy of the trastuzumab-based ADC drug T-DXd for treating HER2-low advanced breast cancer, including TNBC, found that the drug is more effective than chemotherapy and significantly prolongs patients’ progression-free and overall survival [75]. This evidence concerns the gene ERBB2 and breast carcinoma.